Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome

Huda Alalami, Thozhukat Sathyapalan, Stephen Atkin

Research output: Contribution to journalArticle

Abstract

Women with polycystic ovary syndrome (PCOS) have an adverse metabolic profile with an increased risk of prediabetes and type 2 diabetes (T2DM); however, it is unclear if PCOS is associated with increased cardiovascular events in later years independent of the presence of T2DM. Many therapies have been used to treat the differing facets of PCOS, including those for menstrual irregularity, hirsutism, acne and anovulatory infertility. The aim of this review was to evaluate the cardiovascular profiles associated with the medications used in the management of PCOS and evaluate whether they have cardiovascular benefit, detriment or are neutral. The medications reviewed include oral contraceptive pills, antiandrogens, clomiphene and drugs specifically used in diabetes therapy; metformin, glitazones, dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 receptor agonists. This review concludes that therapies that are used to treat these patients appear not to add to the cardiovascular risk and that there is no evidence that any interventional medical therapy may prevent the onset of diabetes in patients with PCOS, though in the case of metformin, this agent may be beneficial in preventing development of gestational diabetes.

Original languageEnglish
JournalTherapeutic Advances in Endocrinology and Metabolism
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Fingerprint

Polycystic Ovary Syndrome
Pharmacology
Metformin
Dipeptidyl-Peptidase IV Inhibitors
Prediabetic State
Androgen Antagonists
Thiazolidinediones
Hirsutism
Clomiphene
Gestational Diabetes
Metabolome
Acne Vulgaris
Therapeutics
Oral Contraceptives
Type 2 Diabetes Mellitus
Infertility
Pharmaceutical Preparations

Keywords

  • androgen
  • cardiovascular risk
  • clomiphene
  • oral contraceptives
  • PCOS
  • Pharmacotherapy

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism

Cite this

@article{75644afd331d4029a679aea92907fa89,
title = "Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome",
abstract = "Women with polycystic ovary syndrome (PCOS) have an adverse metabolic profile with an increased risk of prediabetes and type 2 diabetes (T2DM); however, it is unclear if PCOS is associated with increased cardiovascular events in later years independent of the presence of T2DM. Many therapies have been used to treat the differing facets of PCOS, including those for menstrual irregularity, hirsutism, acne and anovulatory infertility. The aim of this review was to evaluate the cardiovascular profiles associated with the medications used in the management of PCOS and evaluate whether they have cardiovascular benefit, detriment or are neutral. The medications reviewed include oral contraceptive pills, antiandrogens, clomiphene and drugs specifically used in diabetes therapy; metformin, glitazones, dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 receptor agonists. This review concludes that therapies that are used to treat these patients appear not to add to the cardiovascular risk and that there is no evidence that any interventional medical therapy may prevent the onset of diabetes in patients with PCOS, though in the case of metformin, this agent may be beneficial in preventing development of gestational diabetes.",
keywords = "androgen, cardiovascular risk, clomiphene, oral contraceptives, PCOS, Pharmacotherapy",
author = "Huda Alalami and Thozhukat Sathyapalan and Stephen Atkin",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/2042018818805674",
language = "English",
journal = "Therapeutic Advances in Endocrinology and Metabolism",
issn = "2042-0188",
publisher = "Sage Periodicals Press",

}

TY - JOUR

T1 - Cardiovascular profile of pharmacological agents used for the management of polycystic ovary syndrome

AU - Alalami, Huda

AU - Sathyapalan, Thozhukat

AU - Atkin, Stephen

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Women with polycystic ovary syndrome (PCOS) have an adverse metabolic profile with an increased risk of prediabetes and type 2 diabetes (T2DM); however, it is unclear if PCOS is associated with increased cardiovascular events in later years independent of the presence of T2DM. Many therapies have been used to treat the differing facets of PCOS, including those for menstrual irregularity, hirsutism, acne and anovulatory infertility. The aim of this review was to evaluate the cardiovascular profiles associated with the medications used in the management of PCOS and evaluate whether they have cardiovascular benefit, detriment or are neutral. The medications reviewed include oral contraceptive pills, antiandrogens, clomiphene and drugs specifically used in diabetes therapy; metformin, glitazones, dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 receptor agonists. This review concludes that therapies that are used to treat these patients appear not to add to the cardiovascular risk and that there is no evidence that any interventional medical therapy may prevent the onset of diabetes in patients with PCOS, though in the case of metformin, this agent may be beneficial in preventing development of gestational diabetes.

AB - Women with polycystic ovary syndrome (PCOS) have an adverse metabolic profile with an increased risk of prediabetes and type 2 diabetes (T2DM); however, it is unclear if PCOS is associated with increased cardiovascular events in later years independent of the presence of T2DM. Many therapies have been used to treat the differing facets of PCOS, including those for menstrual irregularity, hirsutism, acne and anovulatory infertility. The aim of this review was to evaluate the cardiovascular profiles associated with the medications used in the management of PCOS and evaluate whether they have cardiovascular benefit, detriment or are neutral. The medications reviewed include oral contraceptive pills, antiandrogens, clomiphene and drugs specifically used in diabetes therapy; metformin, glitazones, dipeptidyl peptidase IV inhibitors and glucagon-like peptide-1 receptor agonists. This review concludes that therapies that are used to treat these patients appear not to add to the cardiovascular risk and that there is no evidence that any interventional medical therapy may prevent the onset of diabetes in patients with PCOS, though in the case of metformin, this agent may be beneficial in preventing development of gestational diabetes.

KW - androgen

KW - cardiovascular risk

KW - clomiphene

KW - oral contraceptives

KW - PCOS

KW - Pharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=85058400392&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058400392&partnerID=8YFLogxK

U2 - 10.1177/2042018818805674

DO - 10.1177/2042018818805674

M3 - Article

JO - Therapeutic Advances in Endocrinology and Metabolism

JF - Therapeutic Advances in Endocrinology and Metabolism

SN - 2042-0188

ER -